Bone Biologics (BBLG) Common Equity (2016 - 2017)
Bone Biologics (BBLG) has disclosed Common Equity for 2 consecutive years, with -$10.2 million as the latest value for Q3 2017.
- On a quarterly basis, Common Equity fell 46.24% to -$10.2 million in Q3 2017 year-over-year; TTM through Sep 2017 was -$10.2 million, a 46.24% decrease, with the full-year FY2016 number at -$8.4 million, changed N/A from a year prior.
- Common Equity was -$10.2 million for Q3 2017 at Bone Biologics, down from -$9.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$3.2 million in Q1 2016 to a low of -$10.2 million in Q3 2017.